Beth Hecht - 31 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Beth Hecht
Issuer symbol
XERS
Transactions as of
31 Jan 2025
Net transactions value
-$513,651
Form type
4
Filing time
03 Feb 2025, 19:39:53 UTC
Previous filing
07 Jan 2025
Next filing
21 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $163,436 -45,909 -3.4% $3.56 1,306,885 31 Jan 2025 Direct F1
transaction XERS Common Stock Tax liability $350,215 -98,375 -7.5% $3.56 1,208,510 31 Jan 2025 Direct F1
transaction XERS Common Stock Award $0 +185,000 +15% $0.000000 1,393,510 31 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +300,000 $0.000000 300,000 31 Jan 2025 Common Stock 300,000 $3.56 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
F2 These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F3 This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date.
F4 Upon exercise, the stock appreciation right will be settled in cash.

Remarks:

Chief Legal Officer and Corporate Secretary